Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements

In a report released today, David Lebowitz from Citi reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $364.00.

David Lebowitz has given his Buy rating due to a combination of factors including the promising data updates for Alnylam Pharma’s drug, Amvuttra. The recent 42-week data from the Ph3 HELIOS-B trial demonstrated significant reductions in all-cause mortality and cardiovascular mortality, alongside a decrease in urgent heart failure visits. These results highlight the drug’s strong clinical effects, even when patients are on robust background therapies.
Furthermore, the upcoming presentation of the Ph3 TRITON-CM trial design for another drug, nucresiran, which offers a less frequent dosing schedule, adds to the potential growth prospects for Alnylam. The company’s strategic advancements in the ATTR-CM market, coupled with the expected share price return of 27.6%, underpin Lebowitz’s positive outlook and Buy rating for the stock.

In another report released on May 15, J.P. Morgan also maintained a Buy rating on the stock with a $330.00 price target.